A new platform for profiling degradation-related impurities via exploiting the opportunities offered by ion-selective electrodes: Determination of both diatrizoate sodium and its cytotoxic degradation product
dc.Affiliation | October University for modern sciences and Arts (MSA) | |
dc.contributor.author | Riad S.M. | |
dc.contributor.author | Abd El-Rahman M.K. | |
dc.contributor.author | Fawaz E.M. | |
dc.contributor.author | Shehata M.A. | |
dc.contributor.other | Cairo University | |
dc.contributor.other | Faculty of Pharmacy | |
dc.contributor.other | Analytical Chemistry Department | |
dc.contributor.other | Kasr-El Aini St | |
dc.contributor.other | Cairo | |
dc.contributor.other | 11562 | |
dc.contributor.other | Egypt; October University for Modern Sciences and Arts | |
dc.contributor.other | Faculty of Pharmacy | |
dc.contributor.other | Analytical Chemistry Department | |
dc.contributor.other | 6th of October City | |
dc.contributor.other | Egypt | |
dc.date.accessioned | 2020-01-09T20:41:07Z | |
dc.date.available | 2020-01-09T20:41:07Z | |
dc.date.issued | 2018 | |
dc.description | Scopus | |
dc.description.abstract | Although the ultimate goal of administering active pharmaceutical ingredients (APIs) is to save countless lives, the presence of impurities and/or degradation products in APIs or formulations may cause harmful physiological effects. Today, impurity profiling (i.e., the identity as well as the quantity of impurity in a pharmaceutical) is receiving critical attention from regulatory authorities. Despite the predominant use of spectroscopic and chromatographic methods over electrochemical methods for impurity profiling of APIs, this work investigates the opportunities offered by electroanalytical methods, particularly, ion-selective electrodes (ISEs), for profiling degradation-related impurities (DRIs) compared with conventional spectroscopic and chromatographic methods. For a meaningful comparison, diatrizoate sodium (DTA) was chosen as the anionic X-ray contrast agent based on its susceptibility to deacetylation into its cytotoxic and mutagenic degradation product, 3,5-diamino-2,4,6 triiodobenzoic acid (DTB). This cationic diamino compound can be also detected as an impurity in the final product because it is used as a synthetic precursor for the synthesis of DTA. In this study, four novel sensitive and selective sensors for the determination of both DTA and its cytotoxic degradation products are presented. Sensors I and II were developed for the determination of the anionic drug, DTA, and sensors III and IV were developed for the determination of the cationic cytotoxic impurity. The use of these novel sensors not only provides a stability-indicating method for the selective determination of DTA in the presence of its degradation product, but also permits DRI profiling. Moreover, a great advantage of these proposed ISE systems is their higher sensitivity for the quantification of DTB relative to other spectroscopic and chromatographic methods, so it can measure trace amounts of DTB impurities in DTA bulk powder and pharmaceutical formulation without a need for preliminary separation. � 2018 AOAC International. All rights reserved. | en_US |
dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=23412&tip=sid&clean=0 | |
dc.identifier.doi | https://doi.org/10.5740/jaoacint.16-0369 | |
dc.identifier.doi | PubMed ID 28886756 | |
dc.identifier.issn | 10603271 | |
dc.identifier.other | https://doi.org/10.5740/jaoacint.16-0369 | |
dc.identifier.other | PubMed ID 28886756 | |
dc.identifier.uri | https://t.ly/dOgEM | |
dc.language.iso | English | en_US |
dc.publisher | AOAC International | en_US |
dc.relation.ispartofseries | Journal of AOAC International | |
dc.relation.ispartofseries | 101 | |
dc.subject | October University for Modern Sciences and Arts | |
dc.subject | University for Modern Sciences and Arts | |
dc.subject | MSA University | |
dc.subject | جامعة أكتوبر للعلوم الحديثة والآداب | |
dc.subject | Acetylation | en_US |
dc.subject | Chromatographic analysis | en_US |
dc.subject | Chromatography | en_US |
dc.subject | Degradation | en_US |
dc.subject | Drug products | en_US |
dc.subject | Photodegradation | en_US |
dc.subject | Sodium | en_US |
dc.subject | Active pharmaceutical ingredients | en_US |
dc.subject | Chromatographic methods | en_US |
dc.subject | Electroanalytical method | en_US |
dc.subject | ELectrochemical methods | en_US |
dc.subject | Pharmaceutical formulation | en_US |
dc.subject | Regulatory authorities | en_US |
dc.subject | Selective determination | en_US |
dc.subject | X-ray contrast agents | en_US |
dc.subject | Ion selective electrodes | en_US |
dc.subject | 3,5-diamino-2,4,6-triiodobenzoate | en_US |
dc.subject | contrast medium | en_US |
dc.subject | diatrizoate | en_US |
dc.subject | mutagenic agent | en_US |
dc.subject | analogs and derivatives | en_US |
dc.subject | devices | en_US |
dc.subject | drug contamination | en_US |
dc.subject | electrochemical analysis | en_US |
dc.subject | high performance liquid chromatography | en_US |
dc.subject | ion selective electrode | en_US |
dc.subject | limit of detection | en_US |
dc.subject | pH | en_US |
dc.subject | procedures | en_US |
dc.subject | ultraviolet spectrophotometry | en_US |
dc.subject | Chromatography, High Pressure Liquid | en_US |
dc.subject | Contrast Media | en_US |
dc.subject | Diatrizoate | en_US |
dc.subject | Drug Contamination | en_US |
dc.subject | Electrochemical Techniques | en_US |
dc.subject | Hydrogen-Ion Concentration | en_US |
dc.subject | Ion-Selective Electrodes | en_US |
dc.subject | Limit of Detection | en_US |
dc.subject | Mutagens | en_US |
dc.subject | Spectrophotometry, Ultraviolet | en_US |
dc.title | A new platform for profiling degradation-related impurities via exploiting the opportunities offered by ion-selective electrodes: Determination of both diatrizoate sodium and its cytotoxic degradation product | en_US |
dc.type | Article | en_US |
dcterms.isReferencedBy | Shah, R.B., Khan, M.A., The Science and Regulatory Perspectives of Emerging Controlled Release Dosage Forms (2011) Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice, pp. 337-349. , Jone Wiley & Sons, New York, USA; (2004) Guidance for Industry PAT�A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, , Food and D. Administration DHHS, Rockville, MD; T�nnesen, H.H., (2001) Int. J. Pharm., 225, pp. 1-14; G�r�g, S., (2000) Identification and Determination of Impurities in Drugs, , Elsevier, Amesterdam, Netherlands; Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of Analytical Procedures: Definitions and Terminology, Stability Testing of New Drug Substances and Products Q1A (R2) (2003) International Conference on Harmonization, p. 4. , ICH Guideline Geneva, Switzerland, Step; Baertschi, S.W., (2006) Trends Anal. Chem., 25, pp. 758-767; G�r�g, S., (2006) Trends Anal. Chem., 25, pp. 755-757; Abd El-Rahman, M.K., Salem, M.Y., (2015) Sens. Actuators B Chem., 220, pp. 255-262; El-Rahman, M.K.A., Rezk, M.R., Mahmoud, A.M., Elghobashy, M.R., (2015) Sens. Actuators B Chem., 208, pp. 14-21; El-Rahman, M.K.A., Zaazaa, H.E., ElDin, N.B., Moustafa, A.A., (2015) Talanta, 132, pp. 52-58; Peeters, K., De Maesschalck, R., Bohets, H., Vanhoutte, K., Nagels, L., (2008) Eur. J. Pharm. Sci., 34, pp. 243-249; Srivastava, A.K., Gaichore, R.R., (2013) J. AOAC Int., 96, pp. 133-141; Ragab, M.T., El-Rahman, M.K.A., Ramadan, N.K., El-Ragehy, N.A., El-Zeany, B.A., (2015) Talanta, 138, pp. 28-35; Weiss, R., Hsu, B., Wheeler, L., Norman, A., Riley, R.F., (1981) Invest. Radiol., 16, pp. 517-524; El-Rahman, M.K.A., Riad, S.M., Gawad, S.A.A., Fawaz, E.M., Shehata, M.A., (2015) Spectrochim. Acta A Mol. Biomol. Spectrosc., 136, pp. 1167-1174; Umezawa, Y., B�hlmann, P., Umezawa, K., Tohda, K., Amemiya, S., (2000) Pure Appl. Chem., 72, pp. 1851-2082; Bakker, E., B�hlmann, P., Pretsch, E., (1997) Chem. Rev., 97, pp. 3083-3132; B�hlmann, P., Pretsch, E., Bakker, E., (1998) Chem. Rev., 98, pp. 1593-1688; Telting-Diaz, M., Bakker, E., (2001) Anal. Chem., 73, pp. 5582-5589; Sp�th, A., K�nig, B., (2010) Beilstein J. Org. Chem., 6, p. 32; Gutsche, C.D., Stoddart, J., (1998) Calixarenes Revisited: Monographs in Supramolecular Chemistry, p. 6. , Royal Society of Chemistry, Cambridge, United Kingdom; (2011) The United States Pharmacopeia (USP 34), National Formulary (NF 29), , Authority of the United States Pharmacopeial Convention Rockville, MD; Fawaz, E.M., El-Rahman, M.K.A., Riad, S.M., Shehata, M.A., (2017) Biomed. Chromatogr., 31; Bakker, E., (2015) Anal. Chem., 87 (3), pp. 1981-1990; Baertschi, S.W., Alsante, K.M., Reed, R.A., (2011) Pharmaceutical Stress Testing: Predicting Drug Degradation, , CRC Press, Florida, USA | |
dcterms.source | Scopus |